General Information Job Advert Title: 開発適性評価リード、Analytical Development Lead, Pharmaceutical Developability Location: Tsukuba, Ibaraki Division: Product Research & Development Employment Class: Permanent Description 【About Astellas】 Astellas is a global life sciences company committed to turning innovative science into VALUE
General Information Job Advert Title: Scientist, Upstream Bioprocess Science, CBTL, Product Research & Development Location: Tsukuba, Ibaraki Employment Class: Permanent Description 【募集の背景 / Purpose & Scope】 Upstream Bioprocess Science Lab (USBP) in Chemical & Biological Technology Labs.,
General Information Job Advert Title: Scientist, Downstream Bioprocess Science, CBTL, Product Research & Development Location: Tsukuba, Ibaraki Division: Product Research & Development Employment Class: Permanent Description 【募集の背景 / Purpose & Scope】 Downstream Bioprocess Science Lab (DSBP) in Chemical
General Information Job Advert Title: 【つくば】原薬プロセス研究（ラボオートメーション）サイエンティスト Location: Tskuba, Ibaraki Employment Class: Permanent Description 【募集の背景 / Purpose & Scope】 合成系、バイオベース、およびハイブリッドプラットフォームを含むCMC関連のプロセス技術を特定・評価・優先順位付けし、他のCMCラボと連携して導入する。 ラボオートメーションおよびデジタル技術の導入・運用を通じて、CMCバイオ医薬品プロセス開発における「CMCラボオートメーションおよびDX」コンセプトの現場実装を推進する。 本ポジションでは、チームリーダーやマネージャーの適度なサポートを受けながら、これらの活動を主体的に実行することが求められる。 Identify, assess, and prioritize CMC related process technologies, including synthetic, bio-based, and hybrid platforms and
Who we are We’re a global, midsize CRO that pushes boundaries, innovates and invents because the path to a cure for the world’s most persistent diseases is not paved by those who play it safe. It
JOB DESCRIPTION: Primary Function Provides global or regional leadership for a particular regional or global clinical program. Ensures design and execution of high quality clinical studies to ensure safety and effectiveness of the company’s products. Manages
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
General Information Job Advert Title: 【つくば】分析開発サイエンティスト・外部製造技術統括（SME） Location: Tokodai, Ibaraki Division: External Manufacturing Employment Class: Permanent Description Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies
General Information Job Advert Title: Scientist I, Bioanalytical Sciences Location: Tsukuba,Ibaraki Division: Early Development and Translational Science Employment Class: Permanent Description 【About Astellas】 Astellas is a global life sciences company committed to turning innovative science into
General Information Job Advert Title: Senior Scientist, Applied Safety JP, Applied Safety Location: Tsukuba, Ibaraki Division: Early Development and Translational Science Employment Class: Permanent Description 【About Astellas】 Astellas is a global life sciences company committed to
At Johnson & Johnson,we believe health is everything. Our strength in healthcare innovation empowers us to build aworld where complex diseases are prevented, treated, and cured,where treatments are smarter and less invasive, andsolutions are personal.Through our
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)